Agomab Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 72

Employees

  • Stock Symbol
  • AGMB

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $5.44
  • (As of Friday Closing)

Agomab Therapeutics General Information

Description

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Contact Information

Website
www.agomab.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Posthoflei 1/6
  • 2600 Antwerp
  • Belgium
+32 03
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • Posthoflei 1/6
  • 2600 Antwerp
  • Belgium
+32 03

Agomab Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agomab Therapeutics Stock Performance

As of 20-Nov-2026, Agomab Therapeutics’s stock price is $5.44. Its current market cap is $268M with 49.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.44 $5.62 $5.39 - $17.82 $268M 49.2M 207K -$2.08

Agomab Therapeutics Financials Summary

As of 30-Jun-2026, Agomab Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 503,852
Revenue 0 0 0 0
EBITDA (82,529) (72,054) (50,970) (13,119)
Net Income (77,749) (70,553) (50,065) (12,325)
Total Assets 332,199 180,546 214,730 189,310
Total Debt 1,301 1,473 1,608 1,791
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Agomab Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Agomab Therapeutics‘s full profile, request access.

Request a free trial

Agomab Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Agomab Therapeutics‘s full profile, request access.

Request a free trial

Agomab Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying thera
Drug Discovery
Antwerp, Belgium
72 As of 2026

Maastricht, Netherlands
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agomab Therapeutics Competitors (59)

One of Agomab Therapeutics’s 59 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Ayala Pharmaceuticals Corporation Wilmington, DE
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Abivax Formerly PE-Backed Paris, France
You’re viewing 5 of 59 competitors. Get the full list »

Agomab Therapeutics Patents

Agomab Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026172014-A1 Alk5 activity modulators Pending 17-Feb-2025
WO-2026172015-A1 Novel compounds Pending 17-Feb-2025
WO-2026082960-A1 1,5-naphtyridine and quinoline based inhibitors of alk5 Pending 18-Oct-2024
WO-2026082968-A1 Novel compounds Pending 18-Oct-2024
US-11834507-B2 Anti-met agonist antibody for use in the treatment of colorectal cancer Active 03-Jan-2018 C07K16/2863
To view Agomab Therapeutics’s complete patent history, request access »

Agomab Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Agomab Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Agomab Therapeutics‘s full profile, request access.

Request a free trial

Agomab Therapeutics Acquisitions (1)

Agomab Therapeutics’s most recent deal was a Merger/Acquisition with Origo Biopharma. The deal was made on 26-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Origo Biopharma 26-Oct-2021 Merger/Acquisition Biotechnology
To view Agomab Therapeutics’s complete acquisitions history, request access »

Agomab Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Agomab Therapeutics’s complete esg history, request access »

Agomab Therapeutics FAQs

  • When was Agomab Therapeutics founded?

    Agomab Therapeutics was founded in 2017.

  • Where is Agomab Therapeutics headquartered?

    Agomab Therapeutics is headquartered in Antwerp, Belgium.

  • What is the size of Agomab Therapeutics?

    Agomab Therapeutics has 72 total employees.

  • What industry is Agomab Therapeutics in?

    Agomab Therapeutics’s primary industry is Drug Discovery.

  • Is Agomab Therapeutics a private or public company?

    Agomab Therapeutics is a Public company.

  • What is Agomab Therapeutics’s stock symbol?

    The ticker symbol for Agomab Therapeutics is AGMB.

  • What is the current stock price of Agomab Therapeutics?

    As of 20-Nov-2026 the stock price of Agomab Therapeutics is $5.44.

  • What is the current market cap of Agomab Therapeutics?

    The current market capitalization of Agomab Therapeutics is $268M.

  • Who are Agomab Therapeutics’s competitors?

    Cristal Therapeutics, Ayala Pharmaceuticals, Adaptimmune Therapeutics, Sorrento Therapeutics, and Abivax are some of the 59 competitors of Agomab Therapeutics.

  • What is Agomab Therapeutics’s annual earnings per share (EPS)?

    Agomab Therapeutics’s EPS for 12 months was -$2.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process